Differentiating tardive dyskinesia (TD) from acute extrapyramidal symptoms with Laxman Bahroo, DO

Please see Important Safety Information below.

Tardive dyskinesia (TD) and acute extrapyramidal symptoms (EPS) are involuntary, drug-induced movement disorders that may be challenging to differentiate. Because different approaches are required to manage TD and acute EPS, it is critical to be able to tell the difference.

Watch to learn the distinctions between TD and acute EPS movements with Laxman Bahroo, DO, Department of Neurology, Georgetown University.

Visit to learn more about TD symptoms and potential treatment with INGREZZA® (valbenazine) capsules.

Important Information

INDICATION & USAGE
INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS
Somnolence
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

ADVERSE REACTIONS
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and ＞Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information at

This video is intended for US audiences only.

tardive dyskinesia,TD,uncontrollable movements,involuntary movements,videos,tardive dyskinesia resources,tardive dyskinesia assessment,tardive dyskinesia evaluation,identifying tardive dyskinesia,differentiating tardive dyskinesia,differentiating acute extrapyramidal symptoms,tardive dyskinesia vs acute extrapyramidal symptoms,TD vs acute EPS,